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Brain amyloid-β (Aβ) accumulation is currently considered the main causative pathophysiological
event in Alzheimer’s disease (AD) (Hardy and Higgins, 1992; Karran et al., 2011). Importantly,
this process is thought to precede the onset of AD clinical symptoms by more than two decades,
indicating that early therapeutic strategies prior to symptomatology offer the best chance of success.
In line with this, there is growing attention being paid to the concept of cognitive reserve (CR)
(Stern et al., 1994; Stern, 2002). CR concept is based on extensive epidemiological data indicating
that those with higher lifetime levels of social, physical, and cognitive engagement have a lower
risk of developing dementia despite the presence of brain pathology (Fratiglioni et al., 2004;
Nithianantharajah and Hannan, 2009). Recently, cognitive intervention (CI)—such as cognitive
training (Bahar-Fuchs et al., 2013), cognitive stimulation (Woods et al., 2012), and cognitive
rehabilitation (Clare et al., 2003)—has emerged as a potential non-pharmacological strategy for
the treatment and prevention of AD (Gates and Sachdev, 2014). Although based upon distinct
theoretical constructs, these CI strategies are frequently not distinguished in clinical trials.
Clinical data are supported by compelling evidence from experimental studies, which have
demonstrated that early-life exposure to environmental enrichment (EE), an experimental method
of CR in animals, is able to prevent memory decline in AD-like animal models (Valero et al., 2011;
Verret et al., 2013; Polito et al., 2014). However, the precise mechanisms behind this phenomenon
remain elusive. Environmental enrichment for animals involves stimulating not only their senses
(e.g., smell, sight, touch), but also stimulating their ability to learn and adapt when exposed to
novelty and challenge, including via stimulation of innate behaviors, such as foraging and partner
seeking. The same line of thinking can be applied to humans, on its own scale. This would translate
into exercise, social interaction, learning new things, exploring new environments, keeping the
brain active with cognitive training, i.e., challenging the brain to self-adapt to novelty.
In a recent study, published in Frontiers in Aging Neuroscience, Bezzina et al. (2015) reared
mice harboring a human pathological double mutation in the amyloid precursor protein gene
(APP, model tg2576) in standard or enriched housing conditions for 10 weeks, starting at 3
months of age (pre-Aβ plaque phase). Two weeks after EE exposure, transgenic animals housed
in standard or EE cages presented similar seizure susceptibility to pentylenetetrazole (PTZ), a well-
established GABA receptor antagonist. Moreover, the frequency of interictal spikes—indexed by
electroencephalography (EEG)—after EE was similar between groups. In short, the authors show
that EE is not capable of halting the Aβ-induced aberrant neuronal activity in the Tg2576 AD-like
model. These findings indicate that preventive effects of EE on cognitive decline are not necessarily
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related to changes in neuronal activity. Although negative, these
findings are very relevant since they help rule out abnormal
neuronal activity as amechanism by which EE exerts its beneficial
impact on memory performance.
By contrast, data analyzing the effects of EE on neurogenesis
in AD-like animal models have been mostly positive. EE
exposure for 6 months was able to restore the impaired
hippocampal neurogenesis of a triple transgenic AD-like mouse
model (3xTg-AD, a model harboring human mutations in: APP
(Swedish, KM670/671NL), Tau (MAPT P301L) and Presenilin
1 (PSEN1 M146V) (Rodríguez et al., 2008, 2011). The density
analysis of hippocampal proliferating cells was performed by
immunohistochemistry targeting the presence of phosphorylated
Histone H3 (HH3), and their potential neuronal and glial
phenotype by co-localizing the proliferating cells with the
immature neuronal marker doublecortin (DCX), the mature
neuronal marker (NeuN) or the specific astroglial marker
(GFAP). This very interesting study showed a significant increase
in neuronal proliferating cells (HH3/DCX or HH3/NeuN
positive) in the dentate gyrus of transgenic animals housed in EE.
These results, together with the findings of other experimental
studies, suggest the stimulation of adult neurogenesis as a
potential process by which EE prevents cognitive impairment
in AD-like models (Wolf et al., 2006; Herring et al., 2009;
Mirochnic et al., 2009; Lahiani-Cohen et al., 2011). In
this context, recent evidence indicates that the benefitial
effects of EE are more related to the reorganization of the
neuronal network built by these newborn neurons than to
FIGURE 1 | Hypothetical model depicting the beneficial effects of cognitive intervention on cognitive function on low and high cognitive reserve
individuals as a function of Alzheimer’s disease neuropathology. This hypothetical model exemplifies changes in cognitive function changes over Alzheimer’s
disease (AD) continuum in individuals with high and low cognitive reserve (CR). When AD pathology is absent or possibly below detectable levels using current
biomarkers, individuals with high CR have been shown to perform better on neurophysiological tests than individual with low CR. While cognitive intervention probably
cannot ultimately arrest the progression of AD pathology, as measured by imaging or fluid based biomarkers, it can potentially delay the onset and progression of
cognitive symptoms. In keeping with the observation that individuals with high CR can tolerate greater levels of pathology prior to declines in cognitive performance,
the rate of decline is greater in the high CR group.
the absolute number of newborn neurons per se (Vivar et al.,
2016).
However, the impact of EE on Aβ levels in the brain is still
largely inconclusive (Mainardi et al., 2014; Polito et al., 2014;
Rodríguez et al., 2015). Male APP23, a mouse model expressing
the human APP Swedish double mutation, exposed to EE starting
at 3 months of age until 7 or 18 months showed a marked
cognitive improvement without altering soluble Aβ (7 month-
old) but reducing the number of Aβ plaques at 18 month-old.
These data indicate that EE effect seems to affect Aβ in a distinct
manner.
We are of the opinion that deciphering the underlying
mechanisms of EE can provide important information about
novel therapeutic targets. With currently available treatments
for AD being palliative at best and ineffective at worst—
results from drug trials targeting brain Aβ have been either
inconclusive or negative—non-pharmacological interventions
stimulating cognition in humans hold a measure of promise, not
only for delaying symptomatic onset and the loss of cognitive
functions, but also in terms of unveiling potential targets.
The take-home message from EE studies is clear, however,
and translates to human disease: interventions must occur early
on in the disease course, prior to substantial cognitive deficits
(Figure 1). The question then becomes: how to translate these
findings to clinical research? A promising approach is to study
individuals in the so-called “preclinical” or “asymptomatic at-
risk” stage of AD [please see revised definition of preclinical
AD in Sperling et al. (2011) and Dubois et al. (2016)].
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Defined by the absence of cognitive deficits despite in situ
AD pathology—established using cerebrospinal fluid (CSF) or
positron emission tomography (PET) based biomarkers—cross-
sectional and longitudinal studies suggest this preclinical phase
to span some 20–30 years (Jansen et al., 2015). Based on this,
non-pharmacological interventions directed at CR could be
encouraged in so called “amyloid-positive” individuals believed
to be on the path to symptomatic AD. In this way, we refer to
the concepts of primary and secondary prevention, as defined
by Gates et al. (2011). Primary prevention in the form of
early intervention, aimed at preclinical individuals, in order to
keep them asymptomatic for as long as possible; and secondary
prevention in the form of cognitive training and stimulation for
those who already show subtle and early cognitive impairment
[such as those in the mild cognitive impairment (MCI) phase], to
slow the cognitive decline into AD dementia.
While follow-up studies with longer assessment periods are
essential for more definitive data, early results from several multi-
domain non-pharmacologic intervention studies—addressing
diet, exercise, cognitive training and vascular risk monitoring—
suggest that cognitive functioning can be maintained or even
improved in at-risk elderly individuals (Ngandu et al., 2015).
The incorporation of amyloid biomarkers into such intervention
trials could stand as a valuable adjunct to cognitive and functional
outcomemeasures, possibly allowing for more rapid translational
estimations.
Though EE stimulation has been shown to be a promising
approach for delaying disease progression in animal models
mimicking early onset autosomal dominant AD, which accounts
for less than 5% of cases, what about the far more common
age-related (sporadic) and multifactorial form of AD? How
does EE impact on sporadic models of AD? Here stands a
problem in that models replicating sporadic AD are currently
lacking. In our opinion, major developments in modeling the
sporadic form of AD in rodents will potentially come from
the incorporation of genetic variations that increase the risk of
developing AD, such as the ε4 allele of apolipoprotein E (APOE)
gene, or the R47H allele of the triggering receptor expressed
on myeloid cells 2 (TREM2). Animal models expressing such
combinations of genetic risk factors may better resemble
sporadic AD and ultimately translate into more relevant disease
models.
In conclusion, study designs aiming toward deciphering EE
specific mechanisms are vital and can potentially drive non-
pharmacological strategies. Here we make an argument that the
combination of EE with models that better mimic the sporadic
form of AD, as well as CSF- and PET-based biomarkers, will
potentially provide important insights into AD pathophysiology
and highlight novel therapeutic targets, with strong translational
value.
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